Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 0

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 0
---
Filed pursuant to Rule 253(g)(1)File No. 024-12573

<div align='center'>1,490,000 Units

Consisting of an Aggregate of

1,490,000 Common Shares

and

1,490,000 Warrants to Purchase One Common Share

1,490,000 Common Shares Issuable upon the Exercise of the Warrants

Medicus Pharma Ltd.</div>

We are offering on a “best efforts” basis 1,490,000 units (each, a "Unit") at a price of $2.80 per Unit. Each Unit consists of one common share of Medicus Pharma Ltd. (the "Company"), no par value, and one warrant to purchase one common share (each, a "warrant"), for an aggregate offering of 1,490,000 common shares and 1,490,000 warrants, pursuant to Tier 2 of Regulation A of the United States Securities and Exchange Commission (the “SEC”). Each warrant is immediately exercisable for one of our common shares at an exercise price of $2.80 per share and will expire five years from the date of issuance. The Units will not be certificated and the common shares and warrants comprising the Units are immediately separable and will be issued separately in this offering. Pursuant to this offering circular, we are also offering the 1,490,000 common shares issuable from time to time upon the exercise of the warrants offered hereby.

<div align='center'>______________________</div>

Our common shares and public warrants, with an exercise price of $4.64 and expiration date of November 15, 2029 (the “Public Warrants”) are listed on The Nasdaq Capital Market (the “Nasdaq”), under the symbols "MDCX" and "MDCXW," respectively. The warrants offered hereby will not trade on any U.S. securities exchange and we will not apply for listing on any U.S. securities exchange. Therefore, without an active trading market for the warrants, the liquidity of such warrants will be limited.

The closing price of our common shares and Public Warrants on the Nasdaq on March 6, 2025 were $3.01 and $0.91, respectively.

We are an "emerging growth company" and a "smaller reporting company" under applicable U.S. Securities and Exchange Commission rules and will be eligible for reduced public company disclosure requirements. See"Offering Circular Summary-Implications of Being an